1. Opening Hook
Cipla came armed with double-digit growth stories, lung diagnostics glamour, and ESG promises till 2050.
And yet, the profit line quietly slipped out the back door.
Revenue stayed flat YoY, EBITDA took a deep breath (and exhaled 37%), while PAT decided to reenact a medical drama—flatline first, explanations later. Management, unfazed, kept talking about respiratory dominance, US inhalers, and Africa momentum like nothing happened.
Investors heard “#1 in Albuterol,” analysts heard “exceptional items,” and the stock heard… whatever it wanted.
Read on—because beneath the glossy slides, the real diagnosis comes later, and it’s far more interesting than the headline growth. 😏
2. At a Glance
- Revenue flat at ₹7,074 Cr – Growth took a tea break, blamed macro and math.
- EBITDA down 37% – Costs said “inflation exists,” margins nodded sadly.
- PAT down 57% – Exceptional items doing exceptional damage.
- Net cash ₹10,229 Cr – More cash than excuses, still no buyback noise.
- India 49% of revenue – Home market still carrying the oxygen cylinder.
3. Management’s Key Commentary
“India business is back on a strong double-digit growth trajectory.”
(Translation: Ignore consolidated numbers, zoom into India Rx please 😏)
“Respiratory outperformed IPM growth by 400+ bps.”
(Translation: We own lungs, and we’re not giving them back)
“Albuterol is ranked #1 in the US market with 22% share.”
(Translation: One inhaler to rule them all 💨)
“Lanreotide supply is
